Marc Ribó
Geographical Requirements for the Applicability of the Results of the RACECAT Study to Other Stroke Networks.
Schuler F, Ribó M, Dequatre-Ponchelle N, Rémi J, Dobrocky T, Goeldlin M, Gralla J, Kaesmacher J, Meinel T, Mordasini P, Seiffge D, Fischer U, Arnold M, Kägi G, Jung S. Geographical Requirements for the Applicability of the Results of the RACECAT Study to Other Stroke Networks. J Am Heart Assoc 2023; 12:e029965.
Oct 13, 2023Geographical Requirements for the Applicability of the Results of the RACECAT Study to Other Stroke Networks.
Oct 13, 2023J Am Heart Assoc 2023; 12:e029965
Schuler Florian A F, Ribó Marc, Dequatre-Ponchelle Nelly, Rémi Jan, Dobrocky Tomas, Goeldlin Martina B, Gralla Jan, Kaesmacher Johannes, Meinel Thomas Raphael, Mordasini Pasquale, Seiffge David Julian, Fischer Urs, Arnold Marcel, Kägi Georg, Jung Simon
Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial.
Fischer U, Kaesmacher J, Strbian D, Eker O, Cognard C, Plattner P, Buetikofer L, Mordasini P, Deppeler S, Mendes Pereira V, Albucher J, Darcourt J, Bourcier R, Guillon B, Papagiannaki C, Ozkul-Wermester O, Sibolt G, Tiainen M, Gory B, Richard S, Liman J, Ernst M, Boulanger M, Barbier C, Mechtouff L, Zhang L, Marnat G, Sibon I, Nikoubashman O, Reich A, Consoli A, Lapergue B, Ribó M, Tomasello A, Saleme S, Macian F, Moulin S, Pagano P, Saliou G, Carrera E, Janot K, Hernández-Pérez M, Pop R, Della Schiava L, Luft A, Piotin M, Gentric J, Pikula A, Pfeilschifter W, Arnold M, Siddiqui A, Froehler M, Furlan A, Chapot R, Wiesmann M, Machi P, Diener H, Kulcsar Z, Bonati L, Bassetti C, Mazighi M, Liebeskind D, Saver J, Gralla J, SWIFT DIRECT Collaborators. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet 2022; 400:104-115.
Jul 9, 2022Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial.
Jul 9, 2022Lancet 2022; 400:104-115
Fischer Urs, Kaesmacher Johannes, Strbian Daniel, Eker Omer Faruk, Cognard Christophe, Plattner Patricia S, Buetikofer Lukas, Mordasini Pasquale, Deppeler Sandro, Mendes Pereira Vitor, Albucher Jean François, Darcourt Jean, Bourcier Romain, Guillon Benoit, Papagiannaki Chrysanthi, Ozkul-Wermester Ozlem, Sibolt Gerli, Tiainen Marjaana, Gory Benjamin, Richard Sébastien, Liman Jan, Ernst Marielle Sophie, Boulanger Marion, Barbier Charlotte, Mechtouff Laura, Zhang Liqun, Marnat Gaultier, Sibon Igor, Nikoubashman Omid, Reich Arno, Consoli Arturo, Lapergue Bertrand, Ribó Marc, Tomasello Alejandro, Saleme Suzana, Macian Francisco, Moulin Solène, Pagano Paolo, Saliou Guillaume, Carrera Emmanuel, Janot Kevin, Hernández-Pérez María, Pop Raoul, Della Schiava Lucie, Luft Andreas R, Piotin Michel, Gentric Jean-Christophe, Pikula Aleksandra, Pfeilschifter Waltraud, Arnold Marcel, Siddiqui Adnan, Froehler Michael T, Furlan Anthony J, Chapot René, Wiesmann Martin, Machi Paolo, Diener Hans-Christoph, Kulcsar Zsolt, Bonati Leo H, Bassetti Claudio L, Mazighi Mikaël, Liebeskind David S, Saver Jeffrey L, Gralla Jan, SWIFT DIRECT Collaborators